Icu Medical earnings release, May 7, 2026

Icu Medical Inc (ICUI) · Form 8-K, Item 2.02 · Filed · SEC filing

ICU Medical Announces First Quarter 2026 Results

SAN CLEMENTE, Calif., May 7, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2026.

First Quarter 2026 Results

The following year-over-year results reflect the strategic divestiture of the IV Solutions business on May 1, 2025. First quarter 2026 GAAP revenue declined 12% year-over-year; however, excluding the impact of the IV Solutions divestiture and foreign currency, non-GAAP organic revenue increased 1%.

First quarter 2026 GAAP revenue was $530.2 million, as compared to $604.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2026 was $206.2 million, as compared to $210.1 million in the same period in the prior year. GAAP gross margin for the first quarter of 2026 was 39%, as compared to 35% in the same period in the prior year. GAAP net income for the first quarter of 2026 was $30.1 million, or $1.20 per diluted share, as compared to GAAP net loss of $(15.5) million, or $(0.63) per diluted share, for the first quarter of 2025. Adjusted diluted earnings per share for the first quarter of 2026 was $1.97 as compared to $1.72 for the first quarter of 2025. Adjusted EBITDA was $98.7 million for the first quarter of 2026 as compared to $99.4 million for the first quarter of 2025.

Adjusted EBITDA and adjusted diluted earnings per share are measures calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Use of Non-GAAP Financial Information following the financial statements herein for further discussion and reconciliations of these measures to GAAP measures.

Vivek Jain, ICU Medical’s Chief Executive Officer, said, “First quarter results were generally in line with our expectations."

Revenues by product line for the three months ended March 31, 2026 and 2025 were as follows (in millions):

*On May 1, 2025, we disposed of our IV Solutions business which was included within our Vital Care product line. Vital Care includes contract manufacturing revenue of $4.5 million for the three months ended March 31, 2026, as compared to $5.2 million for the three months ended March 31, 2025.

** Totals may differ from the income statement due to the rounding of product lines.

Conference Call

The Company will host a conference call to discuss its first quarter financial results, today at 4:30 p.m. ET (1:30 p.m. PT). The call can be accessed at (800) 343-4136, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on Event Calendar and clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.

About ICU Medical

ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com.

Financial statements

Income Statement

Three months ended March 31, — (In thousands, except per share data)

Three months ended March 31, – 2026Three months ended March 31, – 2025
TOTAL REVENUES530,225604,702
COST OF GOODS SOLD323,999394,593
GROSS PROFIT206,226210,109
OPERATING EXPENSES:Selling, general and administrative154,566157,233
OPERATING EXPENSES:Research and development21,28023,291
OPERATING EXPENSES:Restructuring, strategic transaction and integration16,80116,697
OPERATING EXPENSES:TOTAL OPERATING EXPENSES192,647197,221
OPERATING EXPENSES:INCOME FROM OPERATIONS13,57912,888
OPERATING EXPENSES:INTEREST EXPENSE, net-16,494-22,031
OPERATING EXPENSES:OTHER EXPENSE, net-1,060-1,763
OPERATING EXPENSES:LOSS BEFORE INCOME TAXES AND EQUITY IN LOSSES OF UNCONSOLIDATED AFFILIATES-3,975-10,906
OPERATING EXPENSES:BENEFIT (PROVISION) FOR INCOME TAXES34,714-4,570
OPERATING EXPENSES:NET INCOME (LOSS) FROM CONSOLIDATED COMPANIES30,739-15,476
OPERATING EXPENSES:EQUITY IN LOSSES OF UNCONSOLIDATED AFFILIATES-607
OPERATING EXPENSES:NET INCOME (LOSS)30,132-15,476
NET INCOME (LOSS) PER SHAREBasic1.22-0.63
NET INCOME (LOSS) PER SHAREDiluted1.2-0.63
WEIGHTED AVERAGE NUMBER OF SHARESBasic24,76424,539
WEIGHTED AVERAGE NUMBER OF SHARESDiluted25,18224,539

Income Statement

(In thousands) (in thousands)

Adjusted EBITDA – Three months ended March 31, – 2026Adjusted EBITDA – Three months ended March 31, – 2025
GAAP net income (loss)30,132-15,476
Non-GAAP adjustments:Interest, net16,49422,031
Non-GAAP adjustments:Stock compensation expense14,01112,179
Non-GAAP adjustments:Depreciation and amortization expense50,02749,445
Non-GAAP adjustments:Restructuring, strategic transaction and integration16,80116,697
Non-GAAP adjustments:Settlements15
Non-GAAP adjustments:Quality system and product-related remediation7,4079,980
Non-GAAP adjustments:Noncash release of loss on contract provision-1,120
Non-GAAP adjustments:Gross profit on contract manufacturing-374
Non-GAAP adjustments:(Benefit) provision for income taxes-34,7144,570
Non-GAAP adjustments:Total non-GAAP adjustments68,547114,902
Non-GAAP adjustments:Adjusted EBITDA98,67999,426

Income Statement

The Company’s U.S. GAAP results for the three months ended March 31, 2026 included special items which impacted the U.S. GAAP measures as follows:

Total revenuesGross profitSelling, general and administrativeResearch and developmentRestructuring, strategic transaction and integrationLoss from operationsInterest expense, net(Loss) income before income taxes and equity in loss of unconsolidated affiliatesBenefit (Provision) for income taxesNet income from consolidated companiesEquity in loss of unconsolidated affiliatedNet income (loss)Diluted earnings (loss) income per share
Reported (GAAP)530,225206,226154,56621,28016,80113,579-16,494-3,97534,71430,739-60730,1321.2
Reported percent of total revenues or (percent of income (loss) before income taxes and equity in earnings of unconsolidated affiliates)3929433-3-1873.36
Contract manufacturing-4,451-374-374-37492-282-282-0.01
Stock compensation expense1,863-11,553-59514,01114,011-3,40110,61010,6100.42
Amortization expense1,265-31,83133,09633,096-8,23124,86524,8650.99
Restructuring, strategic transaction and integration-16,80116,80116,801-4,12612,67512,6750.5
Settlements-151515-41111
Quality system and product-related remediation7,4077,4077,407-1,6995,7085,7080.23
Noncash release of loss on contract provision1,120-1,120332-788193-595-595-0.02
Tax benefit from discrete reserve release and valuation allowance*-33,390-33,390-33,390-1.33
Tax benefit from equity in loss of unconsolidated affiliates-149-149149
Adjusted (Non-GAAP)**525,774216,387112,28720,685$—83,415-16,16266,193-16,00150,192-45849,7341.97
Adjusted percent of total revenues or (percent of (loss) income before income taxes and equity in loss of unconsolidated affiliates for benefit (provision) for income taxes)4121416-31324.210

Income Statement

The Company’s U.S. GAAP results for the three months ended March 31, 2025 included special items which impacted the U.S. GAAP measures as follows:

Total revenuesGross profitSelling, general and administrativeResearch and developmentRestructuring, strategic transaction and integrationIncome (loss) from operations(Loss) income before income taxesProvision for income taxesNet (loss) incomeDiluted (loss) earnings per share
Reported (GAAP)604,702210,109157,23323,29116,69712,888-10,906-4,570-15,476-0.63
Reported percent of total revenues (or percent of (loss) income before income taxes for benefit (provision) for income taxes)3526432-2-41.9-3
Contract manufacturing-5,212
Stock compensation expense1,683-9,868-62812,17912,179-2,9579,2220.37
Amortization expense1,039-31,53332,57232,572-8,02624,5460.99
Depreciation expense reduction - assets held for sale classification-3,223-3,223-3,223790-2,433-0.1

Balance Sheet

(In thousands) (in thousands)

March 31, 2026December 31, 2025
CURRENT ASSETS:Cash and cash equivalents288,330307,963
CURRENT ASSETS:Accounts receivable, net of allowance for doubtful accounts201,077180,515
CURRENT ASSETS:Inventories605,590615,859
CURRENT ASSETS:Prepaid expenses and other current assets118,24886,217
CURRENT ASSETS:TOTAL CURRENT ASSETS1,213,2451,190,554
CURRENT ASSETS:PROPERTY, PLANT AND EQUIPMENT, net445,135451,817
CURRENT ASSETS:OPERATING LEASE RIGHT-OF-USE ASSETS50,79254,470
CURRENT ASSETS:GOODWILL1,485,5611,499,754
CURRENT ASSETS:INTANGIBLE ASSETS, net598,968633,559
CURRENT ASSETS:DEFERRED INCOME TAXES25,64825,891
CURRENT ASSETS:OTHER ASSETS63,49662,877
CURRENT ASSETS:INVESTMENTS IN UNCONSOLIDATED AFFILIATES130,918131,586
CURRENT ASSETS:TOTAL ASSETS4,013,7634,050,508
CURRENT LIABILITIES:Accounts payable173,982154,374
CURRENT LIABILITIES:Accrued liabilities314,570315,337
CURRENT LIABILITIES:Current portion of long-term debt18,75018,750
CURRENT LIABILITIES:Income tax payable10,60210,400
CURRENT LIABILITIES:TOTAL CURRENT LIABILITIES517,904498,861
CURRENT LIABILITIES:LONG-TERM DEBT1,261,8261,265,917
CURRENT LIABILITIES:OTHER LONG-TERM LIABILITIES82,33389,536
CURRENT LIABILITIES:DEFERRED INCOME TAXES14,51437,756
CURRENT LIABILITIES:INCOME TAX LIABILITY25,25834,613
STOCKHOLDERS’ EQUITY:Common stock, $0.10 par value; Authorized — 80,000 shares; Issued —25,186 and 24,688 shares at March 31, 2026 and December 31, 2025, respectively, and outstanding — 24,993 and 24,688 shares at March 31, 2026 and December 31, 2025, respectively2,5192,469
STOCKHOLDERS’ EQUITY:Additional paid-in capital1,465,4671,465,118
STOCKHOLDERS’ EQUITY:Treasury stock, at cost-25,183-22
STOCKHOLDERS’ EQUITY:Retained earnings721,022690,890
STOCKHOLDERS’ EQUITY:Accumulated other comprehensive loss-51,897-34,630
STOCKHOLDERS’ EQUITY:TOTAL STOCKHOLDERS' EQUITY2,111,9282,123,825
STOCKHOLDERS’ EQUITY:TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY4,013,7634,050,508

Cash Flow

Three months ended March 31, — (In thousands) (in thousands)

Three months ended March 31, – 2026Three months ended March 31, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:Net income (loss)30,132-15,476
Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization50,02749,445
Adjustments to reconcile net loss to net cash provided by operating activities:Noncash lease expense4,1734,475
Adjustments to reconcile net loss to net cash provided by operating activities:Stock compensation14,01112,179
Adjustments to reconcile net loss to net cash provided by operating activities:Loss on disposal of property, plant and equipment and other assets1361,696
Adjustments to reconcile net loss to net cash provided by operating activities:Debt issuance costs amortization7741,700
Adjustments to reconcile net loss to net cash provided by operating activities:Undistributed equity in loss of unconsolidated affiliates607
Adjustments to reconcile net loss to net cash provided by operating activities:Other2,9899,214
Changes in operating assets and liabilities, net of amounts acquired:Accounts receivable-24,14522,439
Changes in operating assets and liabilities, net of amounts acquired:Inventories6,088-8,224
Changes in operating assets and liabilities, net of amounts acquired:Prepaid expenses and other current assets-14,347-8,464
Changes in operating assets and liabilities, net of amounts acquired:Other assets-2,363-6,815
Changes in operating assets and liabilities, net of amounts acquired:Accounts payable20,15032,099
Changes in operating assets and liabilities, net of amounts acquired:Accrued liabilities-9,846-36,343
Changes in operating assets and liabilities, net of amounts acquired:Income taxes, including excess tax benefits and deferred income taxes-39,477-6,598
Changes in operating assets and liabilities, net of amounts acquired:Net cash provided by operating activities38,90951,327
CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property, plant and equipment-11,302-14,621
CASH FLOWS FROM INVESTING ACTIVITIES:Deposit received for the sale of a business2,000
CASH FLOWS FROM INVESTING ACTIVITIES:Proceeds from sale of assets142
CASH FLOWS FROM INVESTING ACTIVITIES:Intangible asset additions-1,908-2,232
CASH FLOWS FROM INVESTING ACTIVITIES:Net cash used in investing activities-11,209-16,811
CASH FLOWS FROM FINANCING ACTIVITIES:Principal repayments of long-term debt-4,688-47,750
CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from exercise of stock options133
CASH FLOWS FROM FINANCING ACTIVITIES:Payments on finance leases-658-328
CASH FLOWS FROM FINANCING ACTIVITIES:Tax withholding payments related to net share settlement of equity awards-38,776-8,391
CASH FLOWS FROM FINANCING ACTIVITIES:Net cash used in financing activities-44,122-56,336
CASH FLOWS FROM FINANCING ACTIVITIES:Effect of exchange rate changes on cash-3,2112,958
CASH FLOWS FROM FINANCING ACTIVITIES:NET DECREASE IN CASH AND CASH EQUIVALENTS-19,633-18,862

Cash Flow

(In thousands) (in thousands)

Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow – Three months ended March 31, – 2026Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow – Three months ended March 31, – 2025
Net cash provided by operating activities38,90951,327
Purchase of property, plant and equipment-11,302-14,621
Proceeds from sale of assets142
Free cash flow27,60836,748
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as

“aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the negative thereof or comparable terminology and may include (without limitation) information regarding the Company's expectations, goals and intentions regarding the future and financial outlook for 2026. These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about the Company and assumptions management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to: risks from doing business in foreign countries, including related to tariffs and other barriers to trade; the Company’s ability to compete successfully, including with larger international companies and established local companies; decreased demand for the Company's products; costs related to product development; cost volatility or potential loss of supply of raw materials due to our dependence on single and limited source third-party suppliers; ability to achieve operating efficiencies; risks related to significant sales through our distributors; inflation and foreign currency exchange rates; impacts from global macroeconomic and geopolitical conditions, including from escalated conflicts in the Middle East and associated disruptions to shipping and increased oil costs; healthcare costs and reimbursement levels; disruptions at the FDA and other governmental agencies; damage at the Company’s manufacturing or supply facilities; risks associated with the IV Solutions joint venture and the Smiths Medical integration; risks associated with the timing and resolution of the 2025 warning letter; risks related to protection of our information technology systems and compliance with privacy laws and regulations; risks related to our intellectual property; and the other important factors described under “Risk Factors” in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and our subsequent filings with the SEC, including, without limitation, in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026. Forward-looking statements contained in this press release are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise unless required by law.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Icu Medical earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.